Diagnosis and treatment of basal cell carcinoma: European consensus–based interdisciplinary guidelines
Ketty Peris(Università Cattolica del Sacro Cuore), Alexander Stratigos(National and Kapodistrian University of Athens), Véronique Bataille(King's College London), N. Basset Seguin(Hôpital Saint-Louis), C.A. Morton(University of Stirling), Roland Kaufmann(Robert Koch Institute), Catherine Harwood(Queen Mary University of London), Axel Hauschild(University Hospital Schleswig-Holstein), Josep Malvehy(Universitat de Barcelona), Myrto Trakatelli(Papageorgiou General Hospital), Mark R. Middleton(University of Oxford), Maria Concetta Fargnoli(University of L'Aquila), Lars Bastholt(Odense University Hospital), Eduardo Nagore(Valencia Catholic University Saint Vincent Martyr), V. del Mármol(Université Libre de Bruxelles), Rolf‐Markus Szeimies(Knappschaftskrankenhaus Recklinghausen), Merete Hædersdal(University of Copenhagen), Luca Tagliaferri(Agostino Gemelli University Polyclinic), Iris Zalaudek(Azienda Sanitaria Universitaria Integrata di Trieste), Reinhard Dummer(University Hospital of Zurich), Alexander Eggermont(University Medical Center Utrecht), Claus Garbe(University of Tübingen), Christoph Höller(Medical University of Vienna)
Cited by 589
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors
|Science|2017|5.4k
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
|The Lancet|2012|3k
Combined Vemurafenib and Cobimetinib in <i>BRAF</i> -Mutated Melanoma
|New England Journal of Medicine|2014|2k
Adjuvant Dabrafenib plus Trametinib in Stage III<i>BRAF</i>-Mutated Melanoma
|New England Journal of Medicine|2017|1.5k